{
    "nctId": "NCT00482755",
    "briefTitle": "Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery",
    "officialTitle": "A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients With T1c-T3 Operable Carcinoma of the Breast",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "Feasibility",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Newly diagnosed disease\n  * Stage II-IIIA (T1c, T2, or T3) disease\n  * Unifocal disease\n  * Resectable disease\n* Tumor must be suitable for multiple biopsies and imaging\n* No prior breast cancer\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Absolute granulocyte count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Creatinine normal\n* Calcium \u2264 3 mmol/L\n* Bilirubin normal\n* ALT and AST \u2264 2.5 times upper limit of normal\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other malignancies except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for \u2265 5 years\n* No QTc prolongation (defined as a QTc interval \u2265 500 msec) or other significant ECG abnormalities\n* No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation \u2265 3 beats in a row)\n* No prior or concurrent NYHA class II-IV cardiovascular disease\n* No inadequately controlled hypertension (systolic BP \u2265 140 mm Hg or diastolic BP \u2265 90 mm Hg)\n* No myocardial infarction, cardiac arrhythmia, stable or unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 12 months\n* No pulmonary embolism within the past 12 months\n* No cerebrovascular accident or transient ischemic attack within the past 12 months\n* No serious illness or medical condition that would preclude study compliance including, but not limited to, the following:\n\n  * History of significant neurologic or psychiatric disorder\n  * Active uncontrolled infection\n  * Serious or nonhealing wound, ulcer, or bone fracture\n* No medical condition that could interfere with oral medication intake (e.g., frequent vomiting, malabsorption)\n* No history of allergic reactions attributed to compounds with similar chemical composition to sunitinib malate\n* No preexisting hypothyroidism unless patient is euthyroid on medication\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 7 days since prior and no concurrent CYP3A4 inhibitors, including the following:\n\n  * Azole antifungals (ketoconazole, miconazole)\n  * Verapamil\n  * Clarithromycin\n  * HIV protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfinavir)\n  * Erythromycin\n  * Delavirdine\n  * Diltiazem\n* At least 12 days since prior and no concurrent CYP3A4 inducers, including the following:\n\n  * Rifampin\n  * Phenytoin\n  * Rifabutin\n  * Hypericum perforatum (St. John's wort)\n  * Carbamazepine\n  * Efavirenz\n  * Pentobarbital\n  * Tipranavir\n  * Phenobarbital\n* No prior protein tyrosine kinase inhibitor\n* No prior antiangiogenic agent\n* No prior hormonal therapy, radiotherapy, chemotherapy, surgery, investigational therapy, or other therapy for breast cancer\n* At least 12 days since prior and no concurrent cyclooxygenase-2 inhibitors (e.g., etoricoxib, valdecoxib, celecoxib, dual cyclooxygenase/lipid oxidation, and lumiracoxib)\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, and flecainide)\n* No other concurrent treatment for breast cancer\n* No concurrent coumadin-derivative anticoagulants (e.g., warfarin)\n\n  * Anticoagulants at \u2264 2 mg/day for prophylaxis of thrombosis allowed\n  * Low molecular weight heparin allowed provided INR \u2264 1.5",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}